| Function and Composition of Regulatory B Cells in Participants With Glioblastoma (NCT04128774) | Amsterdam UMC, location VUmc | 2021-01-01 |
| Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9 (NCT03744026) | CarThera | 2019-02-18 |
| Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma (NCT03665545) | University Hospital, Geneva | 2018-10-25 |
| DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma (NCT03714334) | Clinica Universidad de Navarra, Universidad de Navarra | 2018-10-16 |
| A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme (NCT03025893) | Amsterdam UMC, location VUmc | 2018-08-31 |
| Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma (NCT03522298) | Kazia Therapeutics Limited | 2018-05-15 |
| NCT Neuro Master Match - N²M² (NOA-20) (NCT03158389) | University Hospital Heidelberg | 2018-05-07 |
| GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification (NCT03618667) | Samsung Medical Center | 2018-01-22 |
| Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM) (NCT03277638) | Case Comprehensive Cancer Center | 2017-11-29 |
| Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME) (NCT03291977) | Rennes University Hospital | 2017-10-05 |
| NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma (NCT03232424) | Hackensack Meridian Health | 2017-07-26 |
| Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM (NCT03213002) | Northwell Health | 2017-06-13 |
| Study Evaluating the Efficacy of Radiotherapy With SIB-IMRT, Associated With Temozolomide in Glioblastomas (NCT03181477) | Centre Georges Francois Leclerc | 2017-04-07 |
| Ketogenic Diets as an Adjuvant Therapy in Glioblastoma (NCT03075514) | University of Liverpool | 2017-04-01 |
| A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) (NCT02974738) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2016-12-07 |
| Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas. (NCT04610229) | Azienda USL Reggio Emilia - IRCCS | 2016-02-01 |